Originally published In Press as doi:10.1074/jbc.M111639200 on February 1, 2002
J. Biol. Chem., Vol. 277, Issue 17, 14521-14529, April 26, 2002
Linkage of Caspase-mediated Degradation of Paxillin to Apoptosis
in Ba/F3 Murine Pro-B Lymphocytes*
Kee-Oh
Chay,
Sung Sup
Park
, and
J. Frederic
Mushinski§
From the Laboratory of Genetics, NCI, National Institutes of
Health, Bethesda, Maryland 20852
Received for publication, December 6, 2001, and in revised form, January 14, 2002
 |
ABSTRACT |
We have cloned the complete cDNA from mouse
paxillin, a 68-kDa adapter protein found in focal adhesions. We found
that paxillin was degraded by caspases in Ba/F3 cell apoptosis induced
by withdrawal of interleukin-3 (IL-3), a survival factor for this cell,
and by ionizing radiation. Also, paxillin was degraded in
vitro by incubation with recombinant caspase-3. Western blot
analyses of degradation products of overexpressed green fluorescence
protein-tagged paxillin and site-specific mutants demonstrated that
Asp-102 and Asp-301 were early caspase cleavage sites, and
Asp-5, Asp-146, Asp-165, and Asp-222 were late cleavage sites.
Overexpression of paxillin delayed apoptosis of Ba/F3 after IL-3
withdrawal. Furthermore, this anti-apoptotic effect of paxillin was
augmented by a triple mutation in aspartic acids at caspase cleavage
sites. These results suggest that paxillin plays a critical role in
cell survival signaling and that the cleavage of paxillin by caspases might be an important event for focal adhesion disassembly during cell
apoptosis, contributing to detachment, rounding, and death.
 |
INTRODUCTION |
When cells adhere to the extracellular matrix, integrin receptors
initiate signals to cluster more integrins together and to recruit
cytoskeleton proteins (such as talin, tensin, vinculin, zyxin, and
-actinin), adapters (such as paxillin, Crk-associate substrate
(p130CAS)1 and Crk), and
kinases (such as focal adhesion kinase (FAK), and Src) to their
cytoplasmic tails, forming a "focal adhesion complex" (1-3). Focal
adhesions provide not only mechanical support to cells through the
connection with the actin cytoskeleton but also signals necessary for
anchorage-dependent cellular responses such as
proliferation, migration, and inhibition of anoikis, a type of
apoptosis induced by cell detachment (4-6).
Paxillin is a 68-kDa adapter protein discovered in focal adhesions as a
substrate of Src kinase in Src-transformed cells (reviewed in Refs.
7-10) (11). Chicken paxillin (derived from the Latin "Paxillus"
for peg) was purified and characterized as a vinculin-binding protein
from gizzard smooth muscle by Turner et al. (12). Three alternative splicing variants (
,
, and
) (13, 14) of paxillin are known in the human and two (
and
) (15) in the mouse. A
number of paxillin-like homologs have been reported, e.g.
the 48-50-kDa proteins, Hic-5 (16) and leupaxin (17). In structure, paxillin can be divided into two halves. The N-terminal half contains five LD motifs, whereas the C-terminal half contains four LIM domains
(see model in Fig. 8B below). LD motifs
(LDXLLXXL) (18) and LIM domains
(intertwined zinc finger motifs originally described in
homeo-box-containing proteins such as Lin-11,
Isl-1, and Mec-3) (19-20) are
protein-protein interaction motifs and conserved in all known paxillin
homologs. LD motifs are essential for binding with a variety of
proteins such as FAK (21-23), vinculin (23-24), paxillin kinase
linker (an ARF-GAP) (25), actopaxin (26), integrin-linked kinase (27),
and bovine papilloma virus E6 protein (28, 29). The LIM2 and LIM3
domains are important for localization of paxillin to focal adhesions
by a phosphorylation-dependent mechanism (30-31). Paxillin
also binds directly to integrins
4 (32) and
9 (33). Paxillin has two main sites of tyrosine phosphorylation (Tyr-31 and Tyr-118), which are phosphorylated probably
by FAK (34, 35), CAK
(36, 37), or Src (38, 39). These
phosphotyrosine motifs provide binding sites for a SH2 domain of Crk
(35, 40). Accumulating evidence suggests that paxillin plays a pivotal
role in integrin-mediated signal pathways for adhesion, migration, and
anchorage-dependent survival of cells.
Apoptosis, programmed cell death, is accompanied by a succession of
characteristic changes in cellular morphology such as detachment from
substratum, rounding, cytoplasm shrinkage, membrane blebbing, chromatin
condensation, nuclear shrinkage and fragmentation, and DNA
fragmentation (41). It is clear that all these processes are dependent
on proteolytic cleavages by caspases, a family of proteases that are
activated in cascade and degrade many key cellular proteins during
apoptosis. However, the basic mechanisms responsible for these
phenomena and how they are integrated or interdependent have not been
explored in detail. Recent studies have shown that focal adhesions are
disassembled and some of their constituents, such as FAK (42, 43) and
p130CAS (44), are cleaved by caspases during apoptosis. However,
cleavage of these particular components does not appear to be critical
for focal adhesion disassembly during apoptosis, because release of FAK
from focal adhesion precedes cleavage of FAK by caspase (45). It is
more likely that caspase cleavages of components upstream of FAK are
crucial for focal adhesion disassembly. One plausible candidate for the
caspase target that is critical to focal adhesion disassembly is
paxillin, because binding to LD motifs and tyrosine phosphorylation
sites at the N-terminal half of paxillin is essential for recruiting other critical focal adhesion proteins, such as FAK (21-23), vinculin (23-24), Crk (35, 40), p130CAS (46), and actopaxin (26), to the focal
adhesion complex.
IL-3 is a survival and proliferation factor for hematopoietic cells
(47). Ba/F3, a murine pro-B cell line, is dependent on IL-3 for not
only survival and growth but also for its polarized and elongated shape
(48). Ba/F3 cells express a considerable amount of paxillin, and cell
adhesion and migration are essential for lymphocyte functions (37). In
this report, we show that paxillin is degraded by caspase during IL-3
withdrawal and radiation-induced Ba/F3 apoptosis. We studied the
kinetics of caspase-mediated cleavage of paxillin and its cleavage
sites in detail, and we demonstrate that paxillin is anti-apoptotic in
IL-3 withdrawal-induced apoptosis of Ba/F3 cells.
 |
EXPERIMENTAL PROCEDURES |
Materials and Reagents--
Active recombinant caspase-3 was
purchased from Upstate Biotechnology (Lake Placid, NY). Cell-permeable
caspase inhibitors (z-VAD-fmk and z-DEVD-fmk), colorimetric caspase-3
substrate (Ac-DEVD-pNA), N-acetyl-leucyl-leucyl-norleucinal (ALLN), and
N-acetyl-Leu-Leu-methioninal (ALLM), proteasome inhibitor
(clasto-Lactacystin
-lactone), aprotinin, leupeptin, and
4-(2-aminoethyl)benzenesulfonyl fluoride (ABESF) were purchased from
Calbiochem (La Jolla, CA), and CHAPS was obtained from Sigma Chemical
Co. (St. Louis, MO). Alexa 647-conjugated annexin V was from Molecular
Probes (Eugene, OR). Antibodies for paxillin (clone 349), green
fluorescence protein (GFP) (monoclonal and polyclonal), actin (clone
AC-40), and poly(A)DP-rybosyl polymerase (PARP) (polyclonal) were from
Transduction Laboratories (San Diego, CA), CLONTECH
(San Francisco, CA), Sigma, and Santa Cruz Biotechnologies (Santa Cruz,
CA), respectively. Secondary antibodies, horseradish peroxidase-conjugated anti-rabbit and -mouse IgG, were from Amersham Biosciences, Inc. (Piscataway, NJ). Enhanced chemiluminescence substrate kits, Supersignal West Pico and Supersignal West Dura, and
the BCA protein assay kit were from Pierce (Rockford, IL). Protein
G-Sepharose 4 Fast Flow was from Amersham Biosciences, Inc. A
QuikChange site-directed mutagenesis kit was obtained from Stratagene
(La Jolla, CA). pEGFP-C2 and pEGFP-N1 plasmids were from
CLONTECH. The
phagemid cDNA library of
mouse testis was kindly provided by Dr. Konrad Huppi, NCI (National
Institutes of Health).
Cell Culture, IL-3 Deprivation, and
-Irradiation--
The
IL-3-dependent mouse pro-B cell line Ba/F3 was maintained
in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum
and 10% WEHI-3-conditioned media as a source of murine IL-3. To
withdraw IL-3, cells were washed four times by centrifugation and
resuspension in PBS at room temperature (pH 7.4), and 2 × 106 cells were plated into 100-mm dishes containing 10 ml
of pre-warmed IL-3-free medium and incubated in a CO2
incubator for various times with or without exposure to 20 Gy of
-irradiation from a 137Cs source.
PCR Cloning, Sequencing, Vector Construction, and Site-directed
Mutagenesis of Mouse Paxillin--
A cDNA that included the entire
open reading frame of mouse paxillin
was constructed using DNA from
a
phagemid library of mouse testis as a template for a series of
PCR reactions. The 5' and 3' portions of paxillin were amplified
separately using vector sequences and mouse paxillin
-specific
sequences from a central part of the transcript (15).
gt10 forward
primer (5'-GCAAGTTCAGCCTGGTTAAGTCCAAG-3') was paired with paxillin
-specific reverse (5'-TGGGCCATGAACTTGAAATCTGACAG-3') primer, and
gt10 reverse primer (5'-GGTGGCTTATGAGTATTTCTTCCAGGGT-3') was paired
with paxillin
-specific forward primer
(5'-CTGTCAGATTTCAAGTTCATGGCCCA-3'). The two internal paxillin primers
were complementary to one another, and they crossed the splice site
where paxillin
2 is
sometimes inserted by variant splicing (15) to prevent cloning paxillin
. The 5' and 3' halves of paxillin
were PCR amplified three or
four times and sequenced. Consensus sequences (eliminating the
occasional Taq polymerase mistake) were recognized by
comparing the DNA sequences obtained from three or four independent PCR amplifications. A cDNA encoding the entire open reading frame was
obtained by PCR amplification using a pair of primers composed of the
outermost sequences in the initial clones for the two halves of
paxillin and restriction sites for BglII and
EcoRI, respectively. This cDNA was then cloned into
pEGFP-C2 and pEGFP-N1 to create GFP-paxillin and paxillin-GFP fusion
proteins, respectively. All clones were verified by DNA sequencing. A
QuikChange site-directed mutagenesis kit (Stratagene) was used for
in vitro mutagenesis of potential caspase-targeting aspartic
acids (see below) according to the manufacturer's instructions.
Stable Overexpression of Wild-type and Mutant
Paxillins--
cDNAs encoding GFP fusion proteins with paxillin
and their mutants were transfected into BaF/3 cells by electroporation
using Electro Square Porator ECM830 (BTX Division of Genetronics, Inc., San Diego, CA). In detail, Ba/F3 cells (4 × 106) were
washed once with 5 ml of ice-cold 10 mM sodium phosphate buffer (pH 7.4) containing 250 mM sucrose and 1 mM MgCl2, resuspended in 0.4 ml of the same
buffer, and put into 2-mm gap electroporation cuvettes that contained
20 µg of DNA. After gentle mixing and incubation on ice for 10 min,
two electric pulses (375 V, 99-µs duration) were given with a 1-s
interval, and cells were immediately added into 10 ml of pre-warmed
medium in a 100-mm tissue culture dish. Cells were cultured for 2 days
and then cloned into 96-well plates by limiting dilution under
selection with 400 µg/ml G418. Clones that showed green fluorescence
under the fluorescence microscope were selected for expansion, and the
expression level of paxillin and GFP-paxillin fusion proteins was
assayed by Western blot analysis using anti-paxillin or anti-GFP antibodies.
Western Blotting Analysis and Immunoprecipitation--
Cells in
100-mm tissue culture dishes were washed twice by centrifugation at
4 °C and resuspension in cold PBS (pH 7.4). Appropriate amounts of
ice-cold lysis buffer containing 0.5% Triton X-100, 0.5% Nonidet
P-40, 0.5 mM EDTA, 0.5 mM EGTA, 150 mM NaCl, 10 mM Tris-HCl (pH 7.2), 10 µg/ml
aprotinin, 10 µg/ml leupeptin, 1 mM ABESF, and 25 µM each of calpain inhibitors I and II, ALLN and ALLM,
were added to the cell pellets. After brief sonication on ice
and a 15-min centrifugation at maximum speed in the microcentrifuge, supernatants (soluble fraction) were assayed for protein concentration, mixed with SDS-PAGE sample buffer, heated at 100 °C for 5 min, and
loaded onto a 4-20% gradient Tris-glycine polyacrylamide gel. For the
insoluble fraction, the pellet was resuspended and sonicated in an
equal volume of lysis buffer and analyzed as above. Western blots of
these gels were developed with antibodies and chemiluminescence. For
immunoprecipitations, protein G-conjugated beads (10-µl bed volume)
were added to cell extracts (0.5 mg of protein) and continuously inverted for 2 h at 4 °C. After a brief centrifugation, 1 µg
of paxillin antibody and 10 µl of protein G-conjugated beads were added to the supernatant and continuously inverted overnight at 4 °C.
Caspase Assay and Caspase Reaction (49)--
Cell extracts (10 µg of protein) were incubated with 200 µM caspase-3
substrate (Ac-DEVD-pNA) in 100 µl of 25 mM
HEPES buffer (pH 7.5) containing 1 mM EDTA, 2 mM dithiothreitol (DTT), 0.1% CHAPS, and 10% sucrose, for
1 h at 37 °C. Absorbance at 405 nm was measured by a microplate
reader. To study in vitro cleavage of paxillin by caspase,
paxillin was isolated by immunoprecipitation from Ba/F3 cell extracts
as described above. Beads were washed four times with PBS and once by 1 ml of caspase reaction buffer containing 25 mM HEPES (pH
7.5), 1 mM EDTA, 2 mM DTT, 0.1% CHAPS, 10%
sucrose, incubated with 50 µl of reaction buffer in the absence or
presence of 100 ng of active recombinant caspase-3 with or without 10 µM z-DEVD-fmk inhibitor for 1 h at 37 °C, and
analyzed by Western blot analysis of half of each reaction mixture.
Propidium Iodide Staining and Confocal Microscopy--
Cells
(1 × 106) were washed once with PBS containing 1 g/liter sucrose and then fixed and permeabilized overnight in 1 ml of 70% ethanol. After centrifugation at 3000 × g for 10 min, cell pellets were resuspended in PBS containing 1 µg/ml PI and
incubated at room temperature for 1 h. One drop of this suspension
of stained cells was put on a slide glass under a coverslip. Confocal
fluoromicroscopic images were taken with an LSM 510 confocal
laser-scanning microscope (Zeiss, Thornwood, NY).
Annexin V Conjugation Assay--
Cells (1 × 106) were washed once with PBS containing 1 g/liter sucrose
and resuspended in 100 µl of binding buffer containing 10 mM HEPES (pH 7.4), 140 mM NaCl, and 2.5 mM CaCl2 (50). Cells were incubated at room
temperature for 15 min after addition of 5 µl of Alexa 647 (excitation: 647 nm; emission: 665 nm)-conjugated annexin V
stock solution and 1 µg/ml PI and analyzed with the FACSCalibur
system (BD PharMingen immunocytometry system, San Jose, CA).
Protein Assay--
A bicinchoninic acid (BCA) protein assay kit
was used, and bovine serum albumin was used as protein standard
(51).
 |
RESULTS |
Decrease of Paxillin during Ba/F3 Cell Apoptosis Induced by IL-3
Withdrawal and/or
-Irradiation--
Ba/F3 cells are dependent on
IL-3 for their survival and proliferation in culture, and IL-3
withdrawal-induced apoptosis of Ba/F3 cells has been well studied (47,
52-54). Ba/F3 cells are sensitive to ionizing radiation. Exposure to 4 Gy of
-radiation in the absence of IL-3 is enough to induce
apoptosis in this cell line (53), but IL-3 protects this cell from
irradiation-induced apoptosis (55-56). Ba/F3 cells also depend on IL-3
for cell shape (48). They have an elongated shape under optimum growth
conditions, although every culture contains a low percentage of round
cells. The entire cell population becomes round immediately after
removal of IL-3. During the study of regulation of Ba/F3 cell shape by IL-3, we noticed that paxillin protein levels decreased following IL-3
withdrawal. Western blot analysis of cell extracts with monoclonal anti-paxillin antibody revealed two protein bands, and the intensity of
both bands decreased after IL-3 withdrawal (Fig.
1A). The upper 68-kDa band is
paxillin, and the lower 48- or 50-kDa band could be Hic-5 (16) or
leupaxin (17), previously described paxillin-like proteins. The lower
band was not detected by commercial antibody for Hic-5 (Transduction
Laboratories, San Diego, CA, data not shown). Thus, we presume that
this band is leupaxin, for which no commercial antibody is available.
Paxillin was degraded more rapidly after exposure to 20 Gy of
-radiation after withdrawal of IL-3 (Fig. 1B). However,
in neither case did we see the appearance of smaller breakdown products
concurrent with disappearance of p68 paxillin or p48 presumed leupaxin
(Fig. 1). Because the cell extracts used in this Western blot analysis
included only the Triton X-100-soluble fraction, we also checked the
insoluble fraction as described under "Experimental Procedures." No
significant band was detected in the insoluble fraction using the same
paxillin antibody (data not shown). We assumed 1) that Ba/F3 cells
underwent apoptosis after IL-3 withdrawal and
-irradiation, 2) that
paxillin was cleaved by proteases that were activated during the
apoptosis, and 3) that this cleavage destroyed the epitope site for the
monoclonal paxillin antibody or left too small epitope-bearing
fragments to be detected in Western blot analyses.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 1.
Decrease of paxillin in BaF/3 cells after
IL-3 withdrawal with and without
-irradiation. BaF/3 cells were deprived of
IL-3 for the indicated times with (B) or without
(A) exposure to 20 Gy of -radiation. Paxillin and actin
were detected by sequential Western blot analyses of the same blotted
membrane using ECL (20 µg of protein). Protein molecular mass markers
are shown on the left.
|
|
IL-3 withdrawal-induced apoptosis of Ba/F3 cells was analyzed with
annexin V conjugation, to detect early apoptotic cells, and with
parallel PI staining to detect late apoptotic cells (Fig. 2A). Under normal conditions
of culture, more than 99% of the Ba/F3 cell population was negative
for both annexin V and PI staining (Fig. 2A, 0 h).
After 6 h without IL-3, a considerable proportion (19%) of the
cells was converted to annexin V-positive, but the major population
(80%) of the annexin V-positive cells remained negative for PI
staining (early apoptotic cells). The percentage of annexin V- positive
cells increased to 81% of total cells after 24-h incubation. At this
time point, most of annexin V-positive cells (95%) were converted to
positive for PI staining (late apoptotic cells). Apoptosis was much
more rapid in cells exposed to radiation in addition to IL-3
withdrawal. Characteristic early apoptotic changes in nuclear
morphology (Fig. 2B) were revealed by PI staining of
ethanol-fixed cells 8 h after IL-3 withdrawal and
-irradiation. Virtually all the nuclei appeared apoptotic, namely, shrunken and
fragmented, and the chromatin stained brighter and more homogenously (8 h), compared with nuclei in control cells (0 h). The percentage of
apoptotic nuclei is plotted in Fig. 2C, along with a plot
showing the caspase-3 activity of cell extracts at various times after IL-3 withdrawal and
-irradiation. The numbers of apoptotic nuclei and the caspase-3 activities appeared to increase in parallel, but
apoptotic nuclear changes lagged the increase in caspase activity by
about 1 h. Western blot analysis for PARP, a typical caspase-3 substrate that is degraded during apoptosis (49), showed the gradual
decrease of 116-kDa intact protein and the gradual increase of an
85-kDa protein, a well known caspase-cleavage fragment of PARP (Fig.
2D). We concluded that Ba/F3 cells underwent apoptosis after
IL-3 withdrawal and/or
-irradiation, and these apoptotic changes
were accompanied by an activation of caspase activity and a decrease in
paxillin.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 2.
Apoptotic changes in BaF/3 cells after IL-3
withdrawal and -irradiation. BaF/3 cells
were incubated in the absence of IL-3 for the indicated times without
(A) or with (B-D) 20 Gy of -irradiation.
A, annexin V conjugation with parallel PI staining of
IL-3-withdrawn cells was analyzed with flow cytometry. B,
confocal microscopic images after PI staining with ethanol
permeabilization showed apoptotic changes in nuclear morphology after
8 h of incubation. C, apoptotic and normal nuclei
(total 300 cells per time point) were counted under the fluorescent
microscope after PI staining at various times after irradiation. These
values are plotted as percentages of apoptotic nuclei in total number
of cells ( ). Caspase-3 activities of the cells at the same time
points (extracts containing 10 µg of protein) were measured using a
colorimetric caspase-3 substrate as described under "Experimental
Procedures" ( ). D, PARP and its fragments in cell
extracts (20 µg of protein) at each time point were detected by
Western blot analysis using ECL.
|
|
One or More Caspases Were Responsible for the Decrease in Paxillin
during Ba/F3 Cell Apoptosis--
We used several protease inhibitors
to determine which protease(s) might be involved in the loss of
paxillin during Ba/F3 apoptosis. We selected three types of proteases,
caspases, proteasome, and calpain, for testing. Caspases are the main
executioner proteases in apoptosis (57), but proteasomes and calpains
have also been implicated in apoptosis in many cell systems, with
significant cross-talk with caspase pathways (58, 59). The general
caspase inhibitor, z-VAD-fmk (30 µM), completely blocked
apoptotic nuclear changes and paxillin decrease following IL-3
withdrawal and
-irradiation (Fig. 3,
lane 3), whereas the proteasome inhibitor,
clasto-lactacystin
-lactone (5 µM), only
partially inhibited apoptotic nuclear changes and completely inhibited
paxillin loss (Fig. 3, lane 4). However, the combination of
two calpain inhibitors, ALLN and ALLM (50 µM each), did
not lead to any significant abrogation of either apoptotic nuclear
changes or paxillin decrease after IL-3 withdrawal and
-irradiation
(Fig. 3, lane 6). We next tested whether caspase-3, a
principal "executioner" caspase isoform in most apoptosis model systems, could directly digest paxillin in vitro. To this
end, immunoprecipitated paxillin (Fig.
4A) and GFP-paxillin fusion protein (Fig. 4B) were incubated with 100 ng of purified
active caspase-3. Both proteins were effectively degraded by caspase-3, and this degradation was blocked completely by 10 µM
caspase-3-specific inhibitor, z-DEVD-fmk (Fig. 4). A 27-kDa fragment
was detected following GFP-paxillin degradation by caspase-3, and this
degradation product disappeared by addition of 10 µM
caspase-3-specific inhibitor, z-DEVD-fmk (Fig. 4B). These
data did not rule out a contribution by proteasomes to paxillin's
degradation, but, collectively, they strongly indicated that caspase
activity (possibly caspase-3) was involved in both apoptosis and
paxillin breakdown. We then embarked on a detailed investigation of
caspase-mediated paxillin cleavage during apoptosis.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 3.
Decrease of paxillin accompanying BaF/3 cell
apoptosis induced by IL-3 withdrawal and
-irradiation was blocked by caspase inhibitor and
proteasome inhibitor but not by calpain inhibitors. BaF/3 cells
were deprived of IL-3 after 20 Gy of -irradiation in the presence or
absence of 30 µM caspase inhibitor (z-VAD-fmk), 5 µM proteasome inhibitor (clasto-lactacystin
-lactone), 50 µM of both calpain inhibitors I and II
(ALLN and ALLM), or combinations of the above for 4 h. Nuclei of
100 total cells were counted after PI staining of triplicate sets of
samples (average ± S.D.), and paxillin and actin levels were
assayed by Western blot analyses of 20 µg of protein from each cell
extract. Control cells were maintained in IL-3 and not
irradiated.
|
|

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 4.
In vitro cleavage of endogenous
paxillin and exogenous GFP-paxillin by caspase-3. Paxillin
(A) and GFP-paxillin (B) were isolated by
immunoprecipitation of extracts (0.5 mg of protein) of BaF/3 cells and
COS-7 cells that had been transfected with GFP-paxillin cDNA, using
anti-paxillin and anti-GFP antibodies, respectively. The isolated
proteins were incubated in 50 µl of a reaction mixture containing 25 mM HEPES (pH 7.5), 1 mM EDTA, 2 mM
DTT, 0.1% CHAPS, 10% sucrose, in the absence or presence of 100 ng of
active recombinant caspase-3 with or without 10 µM
z-DEVD-fmk for 1 h at 37 °C, and half of each reaction mixture
was analyzed by a Western blot.
|
|
Cloning of Murine Paxillin cDNA into GFP-tagged
Construct--
It is known that the mouse has only two paxillin
splice variants,
and
(15), whereas the human has an additional
-isoform (14). However, cloning and sequencing of full-length mouse
cDNA of paxillin has not been reported. For the detailed study of
paxillin cleavage site by caspases, we cloned the murine paxillin
and
cDNAs by PCR as described under "Experimental
Procedures" and reported the open reading frame sequences to
GenBankTM (accession numbers AF293882 and AF293883).
As expected, murine paxillin showed high homology to human and chicken
paxillins. Murine paxillin
and
were composed of 557 and 591 amino acids, respectively, the same number of amino acids in the
corresponding human isoforms (14). Also, they were variably spliced at
the same sites as in human paxillins. Murine paxillin
showed 89 and
95% identity in cDNA and amino acid sequences, respectively, to
human paxillin
, and 80 and 89% to chicken paxillin. Because no
endogenous paxillin breakdown products were observed by anti-paxillin probing of Western blots (Fig. 1), we adopted enhanced green
fluorescence protein (GFP) as a tag that is big enough to be detected
in the Western blot with even the tiniest of paxillin breakdown
products. Expression constructs for GFP-paxillin and paxillin-GFP
fusion proteins were made by cloning this cDNA into pEGFP-C2 and
pEGFP-N1, respectively. To confirm the expression of fusion proteins,
after transfection of these constructs into COS-7 cells by
electroporation, green fluorescence was observed under the fluorescence
microscope, and 95-kDa fusion proteins were detected by Western blot
analysis using anti-paxillin and anti-GFP antibodies (data not shown).
Overexpressed GFP-paxillin and Paxillin-GFP Fusion Proteins Were
Cleaved during BaF/3 Apoptosis, and the Cleavages Were Inhibited by
Caspase Inhibitor--
GFP-paxillin and paxillin-GFP fusion proteins
(95 kDa) were stably overexpressed in Ba/F3 cells (Fig.
5, 0 h). As with endogenous paxillin
(Fig. 1), these fusion proteins also decreased after IL-3 withdrawal
(Fig. 5, A and C) or the combination of IL-3
withdrawal and
-irradiation (Fig. 5, B and D).
Western blots developed with anti-GFP antibody detected the appearance
of 27- and 38-kDa fragments (Fig. 5, A and B) in
GFP-paxillin-overexpressing cells and a 50-kDa fragment (Fig. 5,
C and D) in the paxillin-GFP-overexpressing cells. The intensities of the 27- and 50-kDa fragments increased in a
reciprocal fashion relative to the decrease of the original protein.
However, the 38-kDa fragment from GFP-paxillin appeared earlier than
the 27-kDa fragment, transiently increased, and finally decreased as
the intensity of the 27-kDa fragment increased. This result indicated
that the proteolytic cleavage that gave rise to the 38-kDa fragment is
an event earlier than that which generated the 27-kDa fragment. All
these and all the following results that use stable overexpressing cell
lines were reproduced in at least three independent clones with
virtually identical results. Fragments smaller than 27 kDa (size of GFP
component) were not observed. In addition, we confirmed that GFP
remained intact for at least 8 h after IL-3 withdrawal and
-irradiation in stable GFP-overexpressing Ba/F3 cells (data not
shown). The diagram in Fig. 5E schematically shows how we
localized the cleavage sites that generated the fragments and located
candidate aspartic acid residues to be tested by mutation. Proteolytic
cleavage of GFP-paxillin and paxillin-GFP and generation of fragments
were also blocked by the caspase inhibitor and the proteasome inhibitor
but not by calpain inhibitors (Fig. 6,
A and C) as seen above for endogenous paxillin,
and the paxillin antibody recognized the 48-kDa protein (Figs. 1 and
6B and 6D). The 27-, 38-, and 50-kDa fragments of
GFP-paxillin and paxillin-GFP were not detected by anti-paxillin
antibody. These three fragments were equal to or larger than GFP in
size, indicating that they bore parts of paxillin that were not
recognized by the anti-paxillin antibody.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 5.
Cleavage of overexpressed GFP-paxillin and
paxillin-GFP fusion proteins in BaF/3 cells during apoptosis induced by
IL-3 withdrawal with and without
-irradiation. BaF/3 cell lines stably
overexpressing mouse paxillin , as GFP-paxillin (A and
B) or paxillin-GFP (C and D) fusion
proteins, were deprived of IL-3 for the indicated times with
(B and D) or without (A and
C) exposure to 20 Gy of -radiation. Fusion proteins in
each cell extract (20 µg of protein) were detected by Western blot
analyses using anti-GFP polyclonal antibody. Panel E shows a
schematic diagram of the two fusion proteins and the cleavage
sites.
|
|

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 6.
IL-3 deprivation and
-irradiation-induced cleavage of GFP-paxillin and
paxillin-GFP fusion proteins in BaF/3 were inhibited by caspases and
proteasome inhibitors but not by calpain inhibitors. BaF/3 cell
lines permanently overexpressing mouse paxillin as GFP-paxillin
(A and B) or paxillin-GFP (C and
D) fusion proteins were deprived of IL-3 after 20 Gy of
-irradiation in the presence or absence of 30 µM
caspase inhibitor (z-VAD-fmk), 5 µM proteasome inhibitor
(clasto-lactacystin -lactone), or 50 µM of
both calpain inhibitors I and II (ALLN and ALLM) for 4 h. GFP-
and/or paxillin-containing proteins were detected by Western blot
analyses of 20 µg of protein from each cell extract using anti-GFP
(A and C) and anti-paxillin (B and
D) antibodies.
|
|
Identification of Apoptosis-induced Caspase-mediated Cleavage Sites
of Paxillin by Site-directed Mutagenesis--
As shown in Fig.
5E, candidate sites of cleavage were predicted, and
site-directed mutations were introduced into GFP-paxillin fusion
proteins by replacing aspartic acid residues near these sites with
glutamic acid or alanine. All amino acid numbers are based on order of
mouse paxillin
amino acids. The first mutations targeted residues 5 and 10 with D5E and D10E mutagenesis. After stable overexpression in
Ba/F3 cells, the breakdown of these mutant fusion proteins and their
fragments was studied by anti-GFP Western blots during the
apoptosis induced by IL-3 withdrawal and
-irradiation. The D5E
mutant (Fig. 7A) but not the
D10E mutant (data not shown) showed a difference in cleavage fragments,
completely lacking the appearance of the expected 27-kDa fragment and a
stable (not transient) appearance of the expected of 38-kDa fragment as
the final product of cleavage. These results indicated that Asp-5 is
the specific cleavage site that generated the 27-kDa fragment. This
makes it the most N-terminal caspase site in paxillin. The second set
of mutations was built on the D5E mutant, adding mutations at Asp-67
and Asp-102 in GFP-paxillin, replacing them with alanine (D5E/D67A and
D5E/D102A). The D5E/102A double mutant showed differences in
cleavage fragments, lacking the 38-kDa fragment but producing a new
ladder of four fragments, 48 kDa, 50 kDa, 56 kDa, and 68 kDa (Fig.
7B). This result indicated that Asp-102 is the specific cleavage site responsible for generating the 38-kDa fragment seen in
Figs. 5B and 7A, and that cleavage at this site
occurred earlier or more effectively than the other sites for the newly
appearing four fragments. A third set of mutations was introduced into
the D5E/D102A double mutant of GFP-paxillin at Asp-146, Asp-165,
Asp-222, or Asp-301 to yield the following triple mutants (3rd-D146E,
3rd-D165E, 3rd-D222E, and 3rd-D301A). All four triple mutants were
stably overexpressed in Ba/F3 cells. These stable cell lines were
incubated for 6 h after IL-3 withdrawal and
-irradiation, and
cleavage fragments from each mutants were analyzed by anti-GFP Western blotting and compared with apoptotic fragments seen in the D5E/D102A double mutant (Fig. 7C). The ladder of fragments from each
triple mutant was different, lacking one band from the four-fragment ladder of the D5E/D102A double mutant. These results indicated that
Asp-146, Asp-165, Asp-222, and Asp-301 were the specific cleavage sites
for the 48-, 50-, 56-, and 68-kDa fragments, respectively. The effects
of caspase inhibitor on cleavages at these four sites were studied
next. As shown in Fig. 7D, 30 µM z-VAD-fmk
completely inhibited the proteolytic breakdown of the D5E/D102A double
mutant into its characteristic four fragments. An additional single
aspartic acid replacement was introduced into the paxillin-GFP fusion
protein (paxillin-GFP D301A) and overexpressed in Ba/F3. This mutant
also showed differences from the apoptotic fragments generated from wild-type paxillin-GFP: missing the characteristic 50-kDa fragment (Fig. 5D), instead producing a 70-kDa new major fragment and
a ladder of larger minor fragments (Fig. 7E). These results
indicated that Asp-301 was the first cleavage site (generating smallest fragment) from the C terminus of paxillin. This conclusion was confirmed by the data from the 3rd-D301A triple mutant of GFP-paxillin, which indicated that Asp-301 is the cleavage site farthest (making the
largest fragment) from the N terminus of paxillin (Fig. 7C, lane 4). When considered in their entirety, these data
indicated that there are no other caspase cleavage sites. These mutants and their characteristic fragments of GFP-paxillin permitted the localization of the epitope site for anti-paxillin monoclonal antibody
(clone 349), which is the most widely used antibody for paxillin
studies. This was done by comparing the anti-GFP and anti-paxillin
Western blot analyses of the D5E/D102A double mutant of GFP-paxillin
and its fragments (Fig. 8A).
The anti-paxillin antibody did not recognize the 48-kDa fragment,
whereas the anti-GFP antibody recognized all the fragments. These data
showed that the epitope for this antibody was lost when paxillin was
cleaved at Asp-146, indicating that it was located between
Asp-146 and Asp-165. Fig. 8B shows a schematic diagram of
the six identified cleavage sites and the epitope site for clone 349 anti-paxillin antibody. The two early cleavage sites are depicted in
larger print, and the four late sites in smaller print.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 7.
Identification of six caspase-cleavage sites
in mouse paxillin by site-directed mutagenesis and stable
overexpression in BaF/3 cells. Mouse GFP-paxillin fusion
protein cDNA was mutated by replacing aspartic acid (D)
with alanine (A) or glutamic acid (E) at six
different sites: D5E, D102A, D146E, D165E, D222E, and D301A.
A: single mutant, D5E; B and D: double
mutant, D5E/D102A; C: four triple mutants with the third
mutation (as indicated), introduced into the D5E/D102A double mutant. A
different single mutation was introduced into paxillin-GFP fusion
protein cDNA (panel E: D301A). All amino acid numbers
are based on order of mouse paxillin amino acids (K.-O. Chay
et al., GenBankTM AF293882). BaF/3 cell lines
stably overexpressing mouse paxillin mutants as GFP fusion proteins
were deprived of IL-3 for the indicated times after exposure to 20 Gy
of -radiation. Fusion proteins and their fragments were detected by
Western blot analyses of 20 µg of protein from each cell extract
using anti-GFP polyclonal antibody.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 8.
Localization of epitope site for
anti-paxillin monoclonal antibody (clone 349) and summary of
caspase-cleavage sites in paxillin. A, the fusion
protein, GFP-paxillin double mutant (D5E/D102A) and its proteolytic
fragments seen 6 h after IL-3 withdrawal and irradiation were
detected by parallel Western blot analysis of the same extract from
BaF/3 cells that express the double mutant using anti-GFP polyclonal
antibody and anti-paxillin monoclonal antibody (clone 349).
B, a schematic diagram of paxillin structure is shown,
indicating the caspase-cleavage sites and the epitope site for
anti-paxillin monoclonal antibody (clone 349). Two early
cleavage sites (Asp-102 (D102), Asp-301 (D301))
are indicated in larger print. LD1-5 and
LIM1-4 designate LD and LIM motifs, respectively
(7-9).
|
|
Inhibition of IL-3 Withdrawal-induced Ba/F3 Apoptosis by Paxillin
Overexpression--
Paxillin has been implicated in integrin-mediated
cell migration, adhesion, and survival pathways (7-10). We tested
whether paxillin was involved in the survival signal pathway of this
cell using the IL-3 withdrawal-induced apoptosis model system and the annexin V conjugation assay for apoptotic cells. Non-transfected Ba/F3
control cells and stable overexpression cell lines of GFP-paxillin fusion proteins (clone 2) and its mutant (clone 12), in which the three
main caspase-cleavage sites had been modified to a non-cleavable form
(3rd-D301A), showed different time courses of apoptosis (Fig. 9A). Before IL-3 withdrawal,
more than 95% of Ba/F3 control and overexpressing cells were negative
for annexin V conjugation (Fig. 9, A and B).
After 4 h of IL-3 withdrawal from Ba/F3 control cells, annexin
V-positive cells appeared. The number of annexin V-positive cells
increased gradually to 52% after 12 h and to 81% after 24 h
in a sigmoid pattern (Fig. 9A). This time course of Ba/F3
apoptosis is well matched to one reported previously (52). But, the
appearance and increase in number of annexin V-positive cells were
delayed significantly in cells with stable overexpression cells of
GFP-paxillin. The number of annexin V-positive increased only to 22%
after 12 h and to 69% after 24 h. These data suggested that
paxillin has anti-apoptotic effects in this IL-3-withdrawal system.
Ba/F3 cells with stable overexpression of the triple mutant
GFP-paxillin (3rd-D301A) showed a time course of apoptosis similar to
that of wild-type-overexpressing cells for 12 h. However,
apoptosis in this cell line showed a prominent delay between 12 and
24 h after IL-3 withdrawal. Only 17 and 52% of cells were
positive for annexin V at 12 and 24 h, respectively. We also
compared the percentage of apoptotic nuclei of these cells after
ethanol permeabilization and PI staining. After 24 h of
IL-3-withdrawal, Ba/F3 control cells showed 82 ± 2% apoptotic
nuclei, whereas Ba/F3 cells with stable overexpression of the wild-type
(clone 2) and the triple mutant GFP-paxillin (3rd-D301A, clone 12)
showed only 67 ± 3% and 38 ± 3% apoptotic nuclei,
respectively. These data suggested that prolonged presence of
overexpressed paxillin (due to loss of caspase cleavage sites) resulted
in a prolonged anti-apoptotic effect. But, the meaning of these data
was limited, because they were from cloned cell lines. To confirm the
anti-apoptotic effect of paxillin and its mutant overexpression, we
analyzed two additional clones from each group and two separate clones
of GFP-overexpressing cells (Fig. 9B). Both additional
clones of GFP-overexpressing cells (clones 2 and 3) showed an extent of
apoptosis after 12 and 24 h of IL-3 withdrawal that was similar to
that of Ba/F3 (Control) cells. Two additional clones of
wild-type GFP-paxillin-overexpressing cells (clones 5 and 6) showed the
significant delay in apoptosis seen for clone 2, and two other clones
from the triple mutant-overexpressing cells (3rd-D301A, clones 13 and
15) showed a further delay seen in the designed clone 12 (Fig.
9A), which was particularly evident after 24 h of IL-3
withdrawal. Because three clones from each group showed consistent
delays in apoptosis, we concluded that overexpressed paxillin has
inhibitory effects on IL-3 withdrawal-induced apoptosis of Ba/F3 cells.
Fig. 9C shows the expression levels of endogenous paxillin,
GFP, and GFP-paxillin fusion proteins in all the cells used. The small
variations in extent of delayed apoptosis of each clone appeared to be
proportional to their expression levels of overexpressed paxillin.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 9.
Inhibition of IL-3 withdrawal-induced Ba/F3
apoptosis by overexpression of paxillin and its mutant.
A, non-transfected Ba/F3 (Control) and
Ba/F3-derived cell lines stably transfected with wild-type GFP-paxillin
cDNA (GFP-paxillin-2) and its triple mutant
(3rd-D301A-12) were deprived of IL-3 for the ten indicated
time points and analyzed with annexin V conjugation assay. The
percentage of annexin V-positive cells was plotted against IL-3
deprivation times. B, percentage of annexin V-positive cells
from control, two different clones overexpressing GFP alone
(GFP-2 and -3), and two other clones
overexpressing wild-type (GFP-paxillin-5 and
GFP-paxillin-6) and the triple mutant
(3rd-D301A-13 and -15) of GFP-paxillin fusion
protein were compared at three time points (0, 12, and 24 h) after
IL-3 withdrawal. C, expression levels of GFP-paxillin,
endogenous paxillin, and GFP in each cell line were compared by Western
blot analysis of extract of cells (20 µg of protein) grown in
complete medium, using anti-paxillin, anti-GFP, and anti-actin
antibodies. Each data point represents the average ± S.D. of
triplicate results.
|
|
 |
DISCUSSION |
IL-3 is produced by activated T cells and acts as a survival and
proliferation factor for many hematopoietic cells (60). IL-3 may play
an important role in the expansion of hematopoietic populations during
inflammation. On the other hand, attenuation of an inflammatory
response may require depletion of IL-3 and the resultant apoptotic
death of the expanded IL-3-dependent cells (61). The murine
pro-B cell, Ba/F3, is dependent on IL-3 for its survival and
proliferation (47). IL-3 also protects this cell from radiation-induced
apoptosis (55, 56). The signal pathway for the anti-apoptotic effect of
IL-3 seems to be separate from the growth-promoting signal pathway,
because treatment Ba/F3 with genistein, a protein-tyrosine kinase
inhibitor, abrogated the IL-3-induced DNA synthesis but not the
IL-3-induced anti-apoptotic effect (62). Ba/F3 is dependent on IL-3 for
its cell shape as well as its survival and proliferation (48). In
normal culture in the presence of appropriate amount of IL-3, Ba/F3
cells, like most cultured lymphocytes, have irregular, elongated, and
polarized shapes. They have actin-rich membrane ruffles at one side of
cells and tubulin-rich tail at the other side. Removal of IL-3 results in the rounding and depolarization of these cells. Salgia et
al. (63) showed the tyrosine phosphorylation of paxillin in
response to IL-3 in 32D cells, a murine promyelocytic line, which is
also dependent on IL-3 for survival and proliferation. They also showed that IL-3 induced a transient interaction between paxillin and vinculin
and transient localization of these focal adhesion proteins to
pseudopodia of 32D cells. IL-3 also induced tyrosine phosphorylation of
paxillin in Ba/F3 with concomitant changes in cellular
morphology.3
In this report, we report that paxillin decreased rapidly in Ba/F3
cells following IL-3 withdrawal (Fig. 1A). This decrease in
paxillin was more rapid and complete following addition of another
apoptotic insult,
-irradiation, to the IL-3 withdrawal (Fig.
1B). In both cases, no breakdown products of paxillin could be detected (Fig. 1). We assumed that paxillin was cleaved into one or
more small fragments by some protease(s) during IL-3 withdrawal-induced apoptosis of Ba/F3 cells. To test this hypothesis, we first studied the
apoptotic changes in Ba/F3 cells after IL-3 withdrawal and/or
-irradiation (Fig. 2). Several parameters for apoptosis such as
PS exposure, nuclear changes, activation of caspase-3, and cleavage of PARP indicated that Ba/F3 cells underwent apoptosis after
IL-3 withdrawal and/or
-irradiation. Furthermore, the time course of
paxillin decrease coincided with the changes in these apoptotic
parameters. We used this combination of IL-3 withdrawal and
-irradiation as an apoptotic insult to study the details of caspase
cleavage of paxillin, because this system gave more rapid results and
might reduce the possibility of further degradation of paxillin
cleavage products by other nonspecific proteases.
To identify the protease(s) involved, we used protease inhibitors
specific for caspase, proteasome, and calpain, all of which can be
activated during apoptosis (57-59). Pan-caspase inhibitor (30 µM z-VAD-fmk) blocked the decrease of paxillin and
apoptotic changes in nuclear morphology completely (Fig. 3). The same
concentration of caspase-3 specific inhibitor (z-DEVD-fmk) showed
similar effects on paxillin decrease but slightly less extensive (80%)
inhibition of nuclear change (data not shown). Cross-talk between the
caspase and proteasome systems is complex. The role of proteasomes in apoptosis seems to be bidirectional. Inhibition of proteasomes induced
apoptosis in most cells, but in some others, it protected from
apoptosis (58). Recently, Hirsch et al. (64) reported that
the proteasome is involved in the premitochondrial arm of apoptosis,
upstream of the caspase cascade. Although lactacystin (5 µM clasto-lactacystin
-lactone) protected
partially Ba/F3 cells from apoptosis (Fig. 3) and inhibited paxillin
degradation, these effects might be from an upstream effect that
decreased caspase activation, rather than direct degradation of
paxillin by proteasome. A ladder of polyubiquitinated paxillin was not observed in Western blot of lactacystin-treated samples, suggesting that ubiquitin/proteasome pathway utilization is minimal in this system. Furthermore, Figs. 5-7 showed that overexpressed paxillin and
its mutants were degraded into products with discreet and considerable
size, which is unlikely due to the action of proteasomes, which chop
proteins into small and different size of oligopeptides (65). Another
family of proteases that are known to cleave proteins into discreet
sizable products during apoptosis and other physiological processes are
calpains (59, 66). Although cleavage of proteins by calpains is
sequence-specific, calpains do not have strict specificity for
substrate sequences (59, 67), whereas caspases are absolutely specific
for aspartic acid residue at the cleavage site (P1 position) (57).
Treatment with calpain-specific inhibitors (ALLN + ALLM, 50 µM of each) did not inhibit either paxillin decrease or
nuclear changes in Ba/F3 cell apoptosis (Fig. 3). So, although caspases
are activated in apoptosis of some cells, our data suggested that
calpain was not critical to paxillin cleavage in Ba/F3 cell apoptosis.
As the third step, we focused on the precise action of caspase.
In vitro incubation of immunoprecipitated paxillin with a purified active form of caspase-3 resulted in the decrease of paxillin,
and it was reversed by caspase-3-specific inhibitor (Fig.
4A). The same phenomena were observed for the GFP-paxillin fusion protein obtained from transient expression in COS-7 cells (Fig.
4B).
We demonstrated that paxillin is cleaved at six different aspartic acid
residues, Asp-5, Asp-102, Asp-146, Asp-165, Asp-222, and Asp-301 (Fig.
8). Intriguingly, all six sites were found only in the N-terminal half
of paxillin, and the C-terminal half of paxillin remained intact until
the late stage of apoptosis (Fig. 5D). As stated previously,
the N-terminal half of paxillin provides binding motifs for a variety
of focal adhesion proteins (21-29), whereas the C-terminal half of
paxillin provides focal adhesion targeting motifs for paxillin (30,
31). The consequences of the intact C-terminal half of paxillin in
apoptotic cell remains to be studied. We simply classified the cleavage
sites into two groups, early (Asp-102 and Asp-301) and late cleavage
sites (Asp-5, Asp-146, Asp-165, and Asp-222) (Fig. 8), based on the
order of appearance of corresponding products (discussed under
"Results"). But the kinetics of cleavage may be more complicated,
and a more detailed study of kinetics with the different caspase
isoforms remains to be undertaken.
We also demonstrated that overexpressed paxillin can inhibit apoptosis
by comparing the time course of apoptosis of Ba/F3 control cells with
Ba/F3 cells overexpressing GFP alone and GFP-paxillin. This result was
reinforced by the additional data that overexpression of a
non-cleavable mutant of paxillin, with mutations at two early sites,
augmented the anti-apoptotic effect. This is the first cellular
demonstration that paxillin can inhibit apoptosis. These results that
suggest caspase-mediated cleavage of paxillin might be a positive
feedback mechanism for caspase-mediated apoptosis. Paxillin may be
involved in integrin-mediated cell survival signals, which somehow
repress activation of caspases. Removal of paxillin by caspase-mediated
cleavage during apoptosis may interrupt these survival signals,
allowing further activation of caspases. The complete details of the
anti-apoptotic role of paxillin remain to be worked out.
 |
ACKNOWLEDGEMENTS |
We sincerely thank Dr. Konrad Huppi for the
cDNA library; Susan Garfield for expert assistance with confocal
microscopy; Dr. Sang Won Kang for critical advice in manuscript
preparation; and Dr. Marina Marini, Dr. Paul Randazzo, and Walter
Schlapkohl for their critical reading of the manuscript.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF293882 and AF293883.
Present address: Laboratory of Immunology, Korea Research
Institute of Bioscience and Biotechnology, Main Bldg., Rm. 2231, 52 Oun-dong, Yusong, Taejon, South Korea 305-333.
§
To whom correspondence should be addressed: Laboratory of Genetics,
NCI, Bldg. 37, Rm. 2B23, National Institute of Health, 9000 Rockville
Pike, Bethesda, MD 20852. Tel.: 301-496-5260; Fax: 301-402-1031;
E-mail: mushinsj@pop.nci.nih.gov.
Published, JBC Papers in Press, February 1, 2002, DOI 10.1074/jbc.M111639200
2
A complete cDNA clone for mouse paxillin
cDNA was also obtained from this library and will be reported elsewhere.
3
L. Y. Romanova, K.-O. Chay, M. V. Blagosklonny,
and J. F. Mushinski, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
p130CAS, Crk-associated substrate;
Crk, chicken tumor virus no. 10 (CT10)
regulator of kinase;
IL-3, interleukin-3;
FAK, focal adhesion kinase;
LD, consensus sequence of LDXLLXXL;
LIM, zinc
finger motifs originally described in homeo-box-containing proteins
such as Lin-II, Isl-I, and Mec-3;
ARF-GAP, ADP-ribosylation factor-GTPase-activating protein;
CAK, cell
adhesion kinase;
z-VAD-fmk, benzoxycarbonyl-Val-Ala-Asp-fluoromethoxy
ketone;
z-DEVD-fmk, benzoxycarbonyl-Asp-Glu-Val-Asp-fluoromethoxy ketone;
ALLN, acetyl-leucyl-leucyl-norleucinal;
ALLM, N-acetyl-Leu-Leu-methioninal;
AEBSF, 4-(2-aminoethyl)benzenesulfonyl fluoride;
GFP, green fluorescence
protein;
PARP, poly-ADP-ribosyl polymerase;
Ac-DEVD-pNA, N-acetyl-Asp-Glu-Val-Asp-p-nitroaniline;
CHAPS, 3-([3-cholamidopropyl]dimethylammonio)-1-propanesulfonate;
PBS, phosphate-buffered saline;
PI, propidium iodide;
DTT, dithiothreitol.
 |
REFERENCES |
| 1.
|
Gilmore, A. P.,
and Burridge, K.
(1996)
Structure
4,
647-651[Medline]
[Order article via Infotrieve]
|
| 2.
|
Critchley, D. R.
(2000)
Curr. Opin. Cell Biol.
12,
133-139[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Miyamoto, S.,
Katz, B. Z.,
Lafrenie, R. M.,
and Yamada, K. M.
(1998)
Ann. N. Y. Acad. Sci.
857,
119-129[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Giancotti, F. G.,
and Ruoslahti, E.
(1999)
Science
285,
1028-1032[Abstract/Free Full Text]
|
| 5.
|
Clark, E. A.,
and Brugge, J. S.
(1995)
Science
268,
233-239[Abstract/Free Full Text]
|
| 6.
|
Craig, S. W.,
and Johnson, R. P.
(1996)
Curr. Opin. Cell Biol.
8,
74-85[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Schaller, M. D.
(2001)
Oncogene.
20,
6459-6472[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Turner, C. E.
(2000)
Nat. Cell Biol.
2,
E231-E236[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Turner, C. E.
(2000)
J. Cell Sci.
113,
4139-4140[Abstract/Free Full Text]
|
| 10.
|
Sattler, M.,
Pisick, E.,
Morrison, P. T.,
and Salgia, R.
(2000)
Crit. Rev. Oncog.
11,
63-76[Medline]
[Order article via Infotrieve]
|
| 11.
|
Glenney, J. R., Jr.,
and Zokas, L.
(1989)
J. Cell Biol.
108,
2401-2408[Abstract/Free Full Text]
|
| 12.
|
Turner, C. E.,
Glenney, J. R., Jr.,
and Burridge, K.
(1990)
J. Cell Biol.
111,
1059-1068[Abstract/Free Full Text]
|
| 13.
|
Salgia, R., Li, J. L., Lo, S. H.,
Brunkhorst, B.,
Kansas, G. S.,
Sobhany, E. S.,
Sun, Y.,
Pisick, E.,
Hallek, M.,
Ernst, T.,
Tantrabahi, R.,
Chen, L. B.,
and Griffin, J. D.
(1995)
J. Biol. Chem.
270,
5039-5047[Abstract/Free Full Text]
|
| 14.
|
Mazaki, Y.,
Hashimoto, S.,
and Sabe, H.
(1997)
J. Biol. Chem.
272,
7437-7444[Abstract/Free Full Text]
|
| 15.
|
Mazaki, Y.,
Uchida, H.,
Hino, O.,
Hashimoto, S.,
and Sabe, H.
(1998)
J. Biol. Chem.
273,
22435-22441[Abstract/Free Full Text]
|
| 16.
|
Fujita, H.,
Kamiguchi, K.,
Cho, D.,
Shibanuma, M.,
Morimoto, C.,
and Tachibana, K.
(1998)
J. Biol. Chem.
273,
26516-26521[Abstract/Free Full Text]
|
| 17.
|
Lipsky, B. P.,
Beals, C. R.,
and Staunton, D. E.
(1998)
J. Biol. Chem.
273,
11709-11713[Abstract/Free Full Text]
|
| 18.
|
Brown, M. C.,
Curtis, M. S.,
and Turner, C. E.
(1998)
Nat. Struct. Biol.
5,
677-678[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Bach, I.
(2000)
Mech. Dev.
91,
5-17[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Dawid, I. B.,
Breen, J. J.,
and Toyama, R.
(1998)
Trends Genet.
14,
156-162[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Tachibana, K.,
Sato, T.,
D'Avirro, N.,
and Morimoto, C.
(1995)
J. Exp. Med.
182,
1089-1099[Abstract/Free Full Text]
|
| 22.
|
Hildebrand, J. D.,
Schaller, M. D.,
and Parsons, J. T.
(1995)
Mol. Biol. Cell
6,
637-647[Abstract]
|
| 23.
|
Turner, C. E.,
and Miller, J. T.
(1994)
J. Cell Sci.
107,
1583-1591[Abstract]
|
| 24.
|
Wood, C. K.,
Turner, C. E.,
Jackson, P.,
and Critchley, D. R.
(1994)
J. Cell Sci.
107,
709-717[Abstract]
|
| 25.
|
Turner, C. E.,
Brown, M. C.,
Perrotta, J. A.,
Riedy, M. C.,
Nikolopoulos, S. N.,
McDonald, A. R.,
Bagrodia, S.,
Thomas, S.,
and Leventhal, P. S.
(1999)
J. Cell Biol.
145,
851-863[Abstract/Free Full Text]
|
| 26.
|
Nikolopoulos, S. N.,
and Turner, C. E.
(2000)
J. Cell Biol.
151,
1435-1447[Abstract/Free Full Text]
|
| 27.
|
Nikolopoulos, S. N.,
and Turner, C. E.
(2001)
J. Biol. Chem.
276,
23499-23505[Abstract/Free Full Text]
|
| 28.
|
Tong, X.,
and Howley, P. M.
(1997)
Proc. Natl. Acad. Sci.
94,
4412-4417[Abstract/Free Full Text]
|
| 29.
|
Tong, X.,
Salgia, R., Li, J. L,
Griffin, J. D.,
and Howley, P. M.
(1997)
J. Biol. Chem.
272,
33373-33376[Abstract/Free Full Text]
|
| 30.
|
Brown, M. C.,
Perrotta, J. A.,
and Turner, C. E.
(1996)
J. Cell Biol.
135,
1109-1123[Abstract/Free Full Text]
|
| 31.
|
Brown, M. C.,
Perrotta, J. A.,
and Turner, C. E.
(1998)
Mol. Biol. Cell
9,
1803-1816[Abstract/Free Full Text]
|
| 32.
|
Liu, S.,
Thomas, S. M.,
Woodside, D. G.,
Rose, D. M.,
Kiosses, W. B.,
Pfaff, M.,
and Ginsberg, M. H.
(1999)
Nature
402,
676-681[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Liu, S.,
Slepak, M.,
and Ginsberg, M. H.
(2001)
J. Biol. Chem.
276,
37086-37092[Abstract/Free Full Text]
|
| 34.
|
Bellis, S. L.,
Miller, J. T.,
and Turner, C. E.
(1995)
J. Biol. Chem.
270,
17437-17441[Abstract/Free Full Text]
|
| 35.
|
Schaller, M. D.,
and Parsons, J. T.
(1995)
Mol. Cell. Biol.
15,
2635-2645[Abstract]
|
| 36.
|
Li, X.,
and Earp, H. S.
(1997)
J. Biol. Chem.
272,
14341-14348[Abstract/Free Full Text]
|
| 37.
|
Salgia, R.,
Avraham, S.,
Pisick, E., Li, J.,
Raja, S.,
Greenfield, A. E.,
Sattler, M.,
Avraham, H.,
and Griffin, J. D.
(1996)
J. Biol. Chem.
271,
31222-31226[Abstract/Free Full Text]
|
|